Elisabeth Heath, MD
Medical Oncology · Rochester, MNNPI 1700823796
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (56.7%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Sanofi at 36.5% of the total. Reporting peaked in 2019 at $68,266 and has fallen 82.5% since, to $11,972 in 2025. Among medical oncology clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 166 payments — averaging $1423.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$86K
- Bayer$23K
- Seagen Inc.$21K
- Astrazeneca UK Limited$21K
- Novartis$15K
- AstraZeneca$14K
- plus $57K from 15 others
Across 1,356 payments — averaging $4416.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$2.5M
- Merck$816K
- Gilead$482K
- Exelixis Inc.$361K
- Bayer$272K
- Corcept Therapeutics$183K
- plus $1.4M from 19 others
What the payments were for
- Consulting fees$134,08557%
- Speaking & faculty fees$87,26837%
- Travel & lodging$12,0305%
- Food & beverage$2,9091%
- Education$350%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 58 | $86,206 |
| Bayer | 17 | $22,974 |
| Seagen Inc. | 25 | $21,468 |
| Astrazeneca UK Limited | 4 | $20,550 |
| Novartis | 6 | $14,541 |
| AstraZeneca | 10 | $13,518 |
| Pfizer | 8 | $13,193 |
| Johnson & Johnson | 9 | $8,209 |
| EMD Serono, Inc. | 1 | $7,125 |
| Janssen Research & Development, LLC | 5 | $7,020 |
| Exelixis Inc. | 2 | $3,995 |
| Bristol Myers Squibb | 3 | $3,728 |
| Sumitomo Pharma America, Inc. | 3 | $2,812 |
| E.r. Squibb & Sons, L.L.C. | 3 | $2,811 |
| Gilead | 2 | $2,432 |
| Dendreon Pharmaceuticals LLC | 4 | $2,156 |
| Astellas Pharma Global Development | 1 | $1,875 |
| Aadi Bioscience, Inc. | 1 | $1,500 |
| Blue Earth Diagnostics | 1 | $142 |
| Myovant Sciences Inc. | 2 | $55 |
| Lilly USA, LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$236,327 in reported general payments places this provider in the 95th percentile of 133 medical oncology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Rochester
- Amit MahipalRochester$746K
- Alton SartorRochester$688K
- Ben GeorgeRochester$579K
- Matthew GoetzRochester$136K
- Thorvardur HalfdanarsonRochester$86K
- Harry YoonRochester$69K
- Karthik GiridharRochester$66K
- Joleen HubbardRochester$59K
- Lionel Aurelien Kankeu FonkouaRochester$58K
- Kaushal ParikhRochester$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.